Elotuzumab

Empliciti

恩必喜凍晶注射劑

300mg/vial

04. ANTINEOPLASTIC AGENTS; ;

04.05. MONOCLONAL ANTIBODIES;;

Anti-SLAMF7

多發性骨髓瘤

X 動物或人體的試驗中或使用經驗發現對胎兒有害，而造成的傷害明顯大於可能的益處。

Unknown

IVF(rate:0.5-5ml/min)
In combination with lenalidomide and dexamethasone
Cycles 1 and 2: 10 mg/kg once weekly on days 1, 8, 15, and 22 of a 28-day treatment cycle.
Cycle 3 and beyond: 10 mg/kg once every 2 weeks on days 1 and 15 of a 28-day treatment cycle; continue until disease progression or unacceptable toxicity.
In combination with pomalidomide and dexamethasone
Cycles 1 and 2: 10 mg/kg once weekly on days 1, 8, 15, and 22 of a 28-day treatment cycle.
Cycle 3 and beyond: 20 mg/kg once every 4 weeks on day 1 of a 28-day treatment cycle; continue until disease progression or unacceptable toxicity.

Fatigue, diarrhea, fever, constipation, cough

1.給藥時需使用含過濾器之輸注套組
2.初始給藥以0.5ml/min速率開始輸注，若無發生任何輸注反應，可每30分鐘逐漸調高輸注速率，最高不可超過5ml/min
3.藥品應冷藏保存。
4.每瓶加入13ml 注射用水(濃度：25mg/ml)，抽取12ml藥水，加入0.9%NaCl注射液中，使其最終濃度為1-6mg/ml(註：注射體積不可>5ml/kg)
5.泡製為輸液後於2-8℃及避光狀態下可存放24小時。

建立者

103617

建立時間

2024-09-02 07:42:40

維護者

103617

維護時間

2024-09-02 07:44:54